Impact of Initial Computed Tomography Findings on Management of Atypical Urinary Cytology of the Upper Urinary Tract

Kotaro Takemura^a Taketo Kawai^a Yusuke Sato^a Jimpei Miyakawa^a
Satoru Taguchi^b Yoshiyuki Akiyama^a Yuta Yamada^a Masaki Nakamura^a
Daisuke Yamada^a Motofumi Suzuki^a Tohru Nakagawa^c Haruki Kume^a

^aDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ^bDepartment of Urology, Kyorin University School of Medicine, Tokyo, Japan; ^cDepartment of Urology, Teikyo University School of Medicine, Tokyo, Japan

Keywords

Upper urinary tract urothelial carcinoma · Upper urinary tract cytology · Atypical · Class III · Repeated RP · Ureteroscopy · Ureterorenoscopy

Abstract

Introduction: Management of patients with atypical urinary cytology (class III) of the upper urinary tract is often complicated because some patients develop upper urinary tract urothelial carcinoma (UTUC). Here, we aimed to help define the optimal management of these patients. **Methods:** We investigated 31 patients who underwent retrograde ureteropyelography (RP) and were diagnosed with atypical findings of upper urinary tract cytology. **Results:** UTUC was revealed in 17 of 31 patients during the follow-up period of 1 year or longer. Tumor-like lesions and wall thickening in the upper urinary tract on initial computed tomography (CT) were significant predictors of UTUC ($p = 0.0002$ and $p = 0.012$, respectively). All 11 patients with tumor-like lesions and 3 of 8 patients with wall thickening on initial CT underwent nephroureterectomy, and UTUC was confirmed histologically. Moreover, 3 of 12 patients with hydronephrosis only or with normal findings later went on to develop UTUC.

Repeated RP performed within 6 months from the initial RP was able to distinguish patients with UTUC from those without, even in individuals with normal CT findings. **Discussion/Conclusion:** Repeated RP based on initial CT findings is recommended in patients with atypical urinary cytology of the upper urinary tract. Nephroureterectomy without repeated RP may be warranted in patients with tumor-like lesions on initial CT findings.

© 2021 The Author(s)

Published by S. Karger AG, Basel

Introduction

Upper urinary tract urothelial carcinoma (UTUC) accounts for 5–10% of urothelial carcinomas [1–3]. Because 60% of UTUC patients have invasive cancer at diagnosis, identification of tumors in earlier stages is crucial for disease management. However, microscopic hematuria, the most common symptom of UTUC, can be often overlooked, which might result in delayed diagnosis [4].

Upper urinary tract cytology, retrograde ureteropyelography (RP), and ureterorenoscopy (or ureteroscopy) are widely used in the diagnosis of UTUC. Urinary cytology of the upper urinary tract is generally accompanied

Fig. 1. Classification based on the initial CT findings. Tumor-like lesions (arrow); Group A (a), wall thickening (arrow); Group B (b), hydronephrosis; Group C (c). CT, computed tomography.

by RP, and specimens are collected by ureteral catheterization before application of a contrast agent for RP. The sensitivity of upper urinary tract cytology is relatively low (43–78%) in UTUC, compared with those of voided urinary cytology in bladder cancer (55–90%) [5]. This presents a significant risk in terms of false-negative results in patients with actual UTUC. Thus, the management of patients with atypical findings (class III) of upper urinary tract cytology is often complicated. In this study, we investigated the development of UTUC in patients with atypical urinary cytology of the upper urinary tract in order to help define the optimal management of this disease.

Methods

Between 2008 and 2018 at the University of Tokyo Hospital, 34 patients with suspected UTUC following computed tomography (CT) or voided urinary cytology underwent RP and were diagnosed with atypical findings (class III) of upper urinary tract cytology. Urinary cytology was defined as follows: class V, conclusive for malignancy; class IV, strongly suggestive for malignancy; class III, atypical but not conclusive for malignancy; and classes I and II, negative for malignancy. We analyzed the clinical data of 31 patients for whom UTUC was revealed during the follow-up period of 1 year or longer; the other 3 patients were excluded from the analysis because of the short observation period or lack of information. After the initial RP, repeated RP including upper urinary tract cytology with/without ureterorenoscopy was performed at the discretion of the attending physician within 6 months, regardless of changes in findings of CT or voided urinary cytology. On the other hand, those patients for whom observation was continued without repeated RP were followed by CT scans and voided urinary cytology every 3–6 months, and reexamination of RP (called nonscheduled RP) with/without ureterorenoscopy was considered when changes appear in CT and/or cytology findings. A positive UTUC diagnosis was defined as patients who were diagnosed with UTUC histologically by biopsy (including at the ini-

tial RP) or nephroureterectomy during the follow-up period. A negative UTUC diagnosis was defined as patients who did not develop UTUC during the follow-up period of 1 year or longer. Fisher's exact test was used for statistical analysis, and a *p* value <0.05 was considered significant.

Results

Table 1 shows the findings of the examination and management of 31 patients with atypical urinary cytology of the upper urinary tract. According to the initial CT findings in the upper urinary tract, we divided the patients into 4 groups: tumor-like lesions in 11 (Group A; Fig. 1a), wall thickening without tumor-like lesions in 8 (Group B; Fig. 1b), hydronephrosis without tumor-like lesions or wall thickening in 4 (Group C; Fig. 1c), and normal findings in 8 (Group D).

In Group A, all 11 patients underwent nephroureterectomy and UTUC was confirmed histologically. Five patients had undergone nephroureterectomy immediately, without repeated RP, ureterorenoscopy, or biopsy. In Group B, UTUC was revealed in 3 of 8 patients and the remaining 5 patients were under surveillance without evidence of UTUC at the median follow-up period of 47 months (23–132 months). In Group C, UTUC developed in one of 4 patients; this patient was diagnosed with UTUC by nonscheduled RP following positive voided urinary cytology and appearance of tumor-like lesions in the ureter upon CT analysis. In Group D, UTUC was revealed in 2 of 8 patients. One positive patient had an extremely small tumor at the vesicoureteral junction that was revealed by ureterorenoscopy; this tumor was resected endoscopically. The other was diagnosed with carcinoma in situ of the upper urinary tract by repeated RP.

Table 1. Examination and management of 31 patients with atypical urinary cytology of the upper urinary tract

Group	Initial CT findings	N	Initial RP, cytology with/without ureterorenoscopy, biopsy				Management and outcome		
			RP	upper tract urinary cytology	ureterorenoscopy	biopsy	management*	histological grading of UTUC	TNM staging of UTUC at diagnosis or follow-up
Group A	Tumor-like lesions (n = 11)	5	Defect	Class III	Tumor observed	Positive for UTUC	Nephroureterectomy	① G3/high, ② G3/high, ③ G3/high, ④ G3/high, ⑤ G3/high	① TisN0M0, ② TaN0M0, ③ T1N0M0, ④ T3N0M0, ⑤ T4N0M0
		1	Defect	Class III	Poor observation due to bleeding	Negative for UTUC	Repeated RP; positive o nephroureterectomy	G3/high	T3N2M0
		4	Defect	Class III	Not performed	Not performed	Nephroureterectomy without repeated RP	① G3/high, ② G2/high, ③ G3/high, ④ G3/high	① TaN0M0, ② T1N0M0, ③ T3N0M0, ④ T3N1M0
		1	Unknown	Class III	Not performed	Not performed	Nephroureterectomy without repeated RP	G2/low	TaN0M0
Group B	Wall thickening without tumor-like lesions (n = 8)	1	Defect	Class III	Tumor observed	Positive for UTUC	Nephroureterectomy	G3/high	T3N0M0
		1	Negative	Class III	Tumor observed	Positive for UTUC	Nephroureterectomy	G3/high	T3N1M0
		1	Negative	Class III	No tumor observed	Negative for UTUC	Repeated RP; negative	na	NED at 132 months
		1	Negative	Class III	No tumor observed	Not performed	Repeated RP; negative	na	NED at 51 months
		1	Stenosis	Class III	Not performed	Not performed	Observation dthascheduled RP; positive onnephroureterectomy	G3/high	TisN2M0
		1	Negative	Class III	No tumor observed	Negative for UTUC	Observation → nonscheduled RP; negative	na	NED at 23 months
		2	Negative	Class III	Not performed	Not performed	Observation	na	NED at 42 and 131 months
Group C	Hydronephrosis without tumor-like lesions or wall thickening (n = 4)	1	Negative	Class III	No tumor observed	Negative for UTUC	Repeated RP; negative	na	NED at 77 months
		1	Stenosis	Class III	Not performed	Not performed	Observation dthascheduled RP with biopsy; positive	G3/high	T1N0M1
		2	Stenosis	Class III	Not performed	Not performed	Observation	na	NED at 16 and 80 months
Group D	Normal findings (n = 8)	1	Negative	Class III	Tumor observed	Positive for UTUC	Endoscopic resection	G2/low	TaN0M0
		1	Negative	Class III	Not performed	Not performed	Repeated RP; positive → nephroureterectomy	G3/high	TisN0M0
		1	Stenosis	Class III	Not performed	Not performed	Repeated RP; negative	na	NED at 15 months
		1	Negative	Class III	Not performed	Not performed	Repeated RP; negative	na	NED at 26 months
		1	Stenosis	Class III	Not performed	Not performed	Observation	na	NED at 53 months
		3	Negative	Class III	Not performed	Not performed	Observation	na	NED at 17, 34, and 78 months

na, not applicable; NED, no evidence of disease; UTUC, urinary tract urothelial carcinoma; CT, computed tomography. * Repeated RP and nonscheduled RP include reexamination of upper tract urinary cytology with/without ureterorenoscopy and biopsy. Repeated RP was performed within 6 months after initial RP. Nonscheduled RP was performed following changes in CT and/or cytology findings after observation.

In total, UTUC was revealed in 17 of 31 patients over a median follow-up period of 30 months (0.2–126 months). UTUC in 15 of 17 patients was high-grade. Patients without UTUC were followed for a median of 47 months (15–132 months).

Tumor-like lesions and wall thickening in the upper urinary tract on initial CT findings were significantly cor-

related with UTUC positivity ($p = 0.0002$ and $p = 0.012$, respectively; Table 2). Although hydronephrosis was not significant ($p = 0.65$), as many as 3 of 12 patients with hydronephrosis only or normal findings later went on to develop UTUC.

Repeated RP with/without ureterorenoscopy was performed in 7 patients; 2 patients were diagnosed with

Table 2. Correlation between initial CT findings and UTUC positivity

Initial CT findings	Total, <i>n</i>	UTUC positive, <i>n</i> (%)	UTUC negative, <i>n</i> (%)	<i>p</i> value
<i>Tumor-like lesions</i>				
Yes	11	11 (100)	0 (0)	0.0002
No	20	6 (30)	14 (70)	
<i>Wall thickening*</i>				
Yes	19	14 (74)	5 (26)	0.012
No	12	3 (25)	9 (75)	
<i>Hydronephrosis†</i>				
Yes	18	11 (61)	7 (39)	0.65
No	13	6 (46)	7 (54)	
<i>Any findings</i>				
Yes	23	15 (65)	8 (35)	0.097
No	8	2 (25)	6 (75)	

UTUC, urinary tract urothelial carcinoma; CT, computed tomography. * Including the cases with tumor-like lesions.

† Including the cases with tumor-like lesions or wall thickening.

UTUC, whereas 5 with negative RP were followed with no evidence of UTUC over a median period of 51 months (15–132 months). This suggests that repeated RP was a robust method for distinguishing patients with UTUC from those without. On the other hand, nonscheduled RP was performed in 3 patients, and UTUC was found in 2, all of whom had metastatic disease, suggesting a delay in correct diagnosis.

Discussion/Conclusion

In patients suspected of having UTUC following CT and/or voided urinary cytology, the combination of RP, upper urinary tract cytology, and ureterorenoscopy increases the sensitivity of UTUC diagnosis. The sensitivity of the combined examinations is 87.5 and 100% for low- and high-grade UTUC, respectively [5]. The predictive value of positive upper urinary tract cytology is high in invasive or high-grade UTUC [6]. The addition of a FISH test may increase both sensitivity and specificity [7, 8]. Meanwhile, positive voided urinary cytology before nephroureterectomy is associated with intravesical recurrence [6].

According to a previous study, 1,320 of 16,299 urinary cytology specimens (8.1%) including voided cytology or

upper urinary tract cytology were diagnosed as atypical, and 271 of 1,320 initial atypical urinary specimens (21%) progressed to positive cytology or confirmed surgical pathology [8]. Although the frequency of atypical upper urinary tract specimens was relatively low in the aforementioned study (82 of 2,482; 3.3%), patients presenting with an atypical upper urinary tract specimen frequently progressed to a malignant diagnosis (31 of 82; 38%) which was often high-grade (17 of 82; 21%) [8]. Thus, patients with atypical cells identified during upper urinary tract cytology should be carefully managed. Indeed, in our study, high-grade UTUC developed in 4 of 18 patients during follow-up despite not being diagnosed at the initial evaluation. Furthermore, UTUC in 15 of 17 patients was high-grade. This result suggests that high-grade cancer cells do not necessarily flow out into the urine even with high-grade UTUC, emphasizing the need for careful follow-up.

We have demonstrated that tumor-like lesions and wall thickening in the upper urinary tract on initial CT findings are significant predictors of UTUC. Especially, all patients with tumor-like lesions were UTUC positive. These results suggest that immediate nephroureterectomy without repeated RP may be warranted in patients with tumor-like lesions on initial CT under sufficient informed consent. Although wall thickening was also found to be a significant predictor in UTUC diagnosis, the actual incidence of UTUC was only 3 in 8 patients. Further studies are required in order to evaluate the predictive potential of wall thickening, and we currently advise against performing immediate surgery.

In this study, repeated RP refers to scheduled examination performed within 6 months after the initial RP regardless of changes in findings of CT or voided urinary cytology. This was discriminated from nonscheduled RP, which was performed following changes in CT and/or cytology findings after observation. Repeated RP appears to be a robust strategy for distinguishing patients with UTUC from those without 2 patients were diagnosed with UTUC and 5 patients with negative results had no evidence of disease at the median follow-up period of 51 months. On the other hand, the diagnosis of UTUC might have been delayed in 2 nonscheduled RP patients in whom metastatic disease was found concomitant with eventual UTUC diagnosis. These results suggest that repeated RP should be considered, especially in patients suspected of having disease at the initial examination.

The present study is associated with some limitations. The primary limitation is the small sample size. The ob-

servation period after the initial RP may not have been long enough to confirm UTUC positivity in some patients. Moreover, the diagnosis of urinary cytology varies depending on the facility or pathologists. Further studies will be required to support the initial findings of our study.

Our results suggest that repeated RP with/without ureteroscopy based on initial CT findings in the upper urinary tract or other factors should be adopted in clinical practice. This may improve the management of patients with atypical urinary cytology of the upper urinary tract and simplify what has historically been a complex disease to manage.

Statement of Ethics

This study was approved by the Ethics Committee at the University of Tokyo Hospital (Approval number: 3124). Written informed consent to participate and for publication was obtained from the patients.

References

- 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin*. 2016;66(1):7–30.
- 2 Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. *J Urol*. 2000;164(5):1523–5.
- 3 Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). *World J Urol*. 2017; 35(3):379–87.
- 4 Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. *Cancer*. 2009;115(6):1224–33.
- 5 Wang L, Pambuccian SE, Wojcik EM, Barkan GA. Diagnosis of upper tract urothelial carcinoma: a comparative study of urinary cytology and surgical biopsy. *J Am Soc Cytopathol*. 2015;4(1):3–9.
- 6 Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, et al. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. *Urol Oncol*. 2014;32(1):48–26.
- 7 Xu C, Zeng Q, Hou J, Gao L, Zhang Z, Xu W, et al. Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients. *Urology*. 2011;77(3):636–41.
- 8 Muus Ubago J, Mehta V, Wojcik EM, Barkan GA. Evaluation of atypical urine cytology progression to malignancy. *Cancer Cytopathol*. 2013;121(7):387–91.

Conflict of Interest Statement

The authors declare no conflicts of interest.

Funding Sources

The authors did not receive any funding.

Author Contributions

K.T. collected data and wrote the manuscripts. T.K. contributed to concept of this paper, interpreted the data, and prepared the manuscripts. Y.S. and J.M. collected data. S.T., Y.A., Y.Y., M.N., D.Y., M.S., and T.N. reviewed the manuscripts. H.K. contributed to concept of this paper and reviewed the manuscripts. All authors read and approved the final manuscripts.